Biotech/Medical Tech Stock News from Investorideas.com: December 2024

Friday, December 20, 2024

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Hemopurifier Bird Flu Update

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Hemopurifier Bird Flu Update

Investorideas.com (www.investorideas.com) a go-to platform for big investing ideas for stock traders, including biotech and medical tech stocks reports on trading and news for Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

The stock has had big gains in this morning’s trading session following an update on the company’s Hemopurifier device in the treatment of Bird Flu.

The stock is trading at $0.5761, up 0.1427, gaining 32.7745% on volume of over 55 Million shares as of this report. The stock had a day’s high of $0, 8275.

Today Aethlon provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."

Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including a case of severe infection in Louisiana, and yesterday's declaration of a state of emergency in California.

Paid News Dissemination of behalf of AEMD.

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/12201AEMD-Hemopurifier-Bird-Flu-Update.asp

The Aethlon Hemopurifier is an investigational extracorporeal medical device designed to remove enveloped viruses and extracellular vesicles from the bloodstream. The device incorporates plasma separation, size exclusion, and affinity binding to a proprietary resin containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a medical grade diatomaceous earth. Enveloped viruses and extracellular vesicles contain the sugar mannose on their surface, which is the therapeutic target of the GNA.

Aethlon has previously contracted Battelle labs to examine the in vitro removal of influenza viruses including H5N1 by a scaled down version of the Aethlon Hemopurifier. In this experiment, cell culture media was spiked with the H5N1 virus and continuously circulated over the device. Samples were taken periodically to examine viral removal by the device. In this study, a miniature version of the device removed 99% of H5N1 following 6 hours of treatment.

While the Aethlon Hemopurifier has not yet been used to treat patients with severe influenza, including those infected with H5N1, it has been used in 38 patients across 164 distinct treatment sessions, targeting diseases such as hepatitis C, HIV, and in patients critically ill due to COVID-19 and Ebola. The Hemopurifier has a "breakthrough device" designation with the FDA for life-threatening viruses for which there is no effective treatment.

Current treatment guidelines from the Center for Disease Control and Prevention (https://www.cdc.gov/bird-flu/hcp/novel-av-treatment-guidance/), for hospitalized patients with suspected Bird Flu (H5N1), are to initiate antiviral therapy as soon as possible with Oseltamivir, with or without combination therapy with Baloxavir. Clinical failures during Oseltamavir therapy due to the development of antiviral resistance have been observed in hospitalized patients with H5N1. This phenomenon raises the possibility that novel treatment strategies may be required. Aethlon Medical will monitor this situation closely and interact with hospitals, the state of California, and the FDA as appropriate if cases mount and currently available treatments are not effective.

IPOs in Biotech, Cleantech, Mining & Entertainment; (Nasdaq: $ACOG), (CSE: $ONCO.C), (CSE: $DTR.C), (Nasdaq: $ADUR), (Nasdaq: $CGTL), (Nasdaq: $DMN), (NYSE: $GRO), (CSE: $BRAZ.C), (NYSE American: $VENU)

IPOs in Biotech, Cleantech, Mining & Entertainment; (Nasdaq: $ACOG), (CSE: $ONCO.C), (CSE: $DTR.C), (Nasdaq: $ADUR), (Nasdaq: $CGTL), (Nasdaq: $DMN), (NYSE: $GRO), (CSE: $BRAZ.C), (NYSE American: $VENU)

December 20, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech, Cleantech, Mining & Entertainment sectors.

New companies are all recent IPOs on Nasdaq, NYSE or CSE.

New stocks added today: Alpha Cognition Inc. (Nasdaq:ACOG), Onco-Innovations Limited (CSE: ONCO), DiagnosTear Technologies Inc. (CSE:DTR), ADURO CLEAN TECHNOLOGIES INC. (Nasdaq:ADUR), Creative Global Technology Holdings Ltd (Nasdaq:CGTL), Grafiti Holding Inc. (Nasdaq:DMN), Brazil Potash Corp. (NYSE:GRO), Canary Gold Corp. (CSE: BRAZ), Venu Holding Corp (NYSE American:VENU).

Read this in full at https://www.investorideas.com/news/2024/main/12201Stocks.asp

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

New Stocks Added to the Biotech Directories:

Alpha Cognition Inc. (Nasdaq:ACOG) is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Onco-Innovations Limited (CSE: ONCO) is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. Onco’s commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

DiagnosTear Technologies Inc. (CSE:DTR) is focused on the diagnosis of front-of-the-eye diseases at the point of care, by analyzing the composition of the tear fluid using its proprietary non invasive TeaRx™ technology and currently has two products for diagnosis of Dry Eye Disease and Red Eye causes.

New Stocks Added to the Cleantech Directories:

ADURO CLEAN TECHNOLOGIES INC. (Nasdaq:ADUR) is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company’s Hydrochemolytic™ technology relies on water as a critical agent in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into resources for the 21st century.

Creative Global Technology Holdings Ltd (Nasdaq:CGTL) is dedicated to extending the life of consumer electronics through effective recycling, supporting a sustainable circular economy and reducing electronic waste. The Company connects supply and demand for pre-owned devices, maximizing their utility. Specializing in sourcing and reselling recycled smartphones, tablets, and laptops, CGTL facilitates the flow of retired devices from affluent markets like the U.S. and Japan to developing regions in need of affordable technology. With a lean inventory and efficient logistics, CGTL ensures quick inspection and availability for clients. CGTL has also expanded into retail sales and device rentals, providing Hong Kong residents access to quality recycled electronics and meeting short-term needs.

Grafiti Holding Inc. (Nasdaq:DMN) is on a mission to cause a paradigm shift for safer, smarter motorcycling. With its development offices in San Rafael, California, Damon is led by entrepreneurs and executives from world-class EV and technology companies. Anchored by the groundbreaking HyperDrive™ electric powertrain, all Damon motorcycles are set to deliver power and range that exceeds that of gas without the noise, emissions, or maintenance hassles. Damon has captured the attention of the motorcycling world cutting edge designs and innovative safety technologies including CoPilot™ and Shift™, which are attracting a new generation of motorcycle riders. With strong consumer interest in the US and abroad, Damon aims to set the standard for motorcycle safety and sustainability worldwide.

New Stocks Added to the Mining Directories:

Brazil Potash Corp. (NYSE:GRO) is an exploration and development company with a potash mining project (the “Autazes Project”) located in the state of Amazonas, Brazil. The Company’s technical operations are based in Autazes, Amazonas, Brazil and Belo Horizonte, Minas Gerais, Brazil, and its corporate office is in Toronto, Ontario, Canada. The Company is in the pre- revenue development stage and has not yet commenced any mining operations. The Company’s plan of operations for the next few years includes securing all required environmental licenses for the Autazes Project, and, subject to securing sufficient funds, commencing all phases of the construction of the Autazes Project.

Canary Gold Corp. (CSE: BRAZ) a mineral exploration company whose principal business is the acquisition and exploration of gold mineral exploration properties, with a focus in Rondônia, Brazil. The Company may acquire up to a 70% undivided right, title and interest in one gold mineral property in Brazil, the Rio Madeira Property. The Rio Madeira Property consists of an aggregate of eight applications for exploration licenses covering an area of 68,445 hectares in Rondônia, Brazil.

New Stocks Added to the Entertainment Directories:

Venu Holding Corp (NYSE American:VENU) founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers. Unique to Colorado Springs, Notes Eatery, and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience. VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents, three-time Super Bowl Champion and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape.

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

800 665 0411

Investorideas wishes everyone a Healthy, Happy Holiday Season and a Prosperous New Year!

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

SAN DIEGO - December 20, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."

Paid News Dissemination of behalf of AEMD.

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/12201AEMD-Hemopurifier-H5N1-Bird-Flu.asp

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in patients with solid tumors in our oncology clinical trials; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trials in Australia and India, including on the timeline expected by the Company; whether or not patients that are enrolled in the Company's clinical trials will respond to PD-1 antibody monotherapy; the number of patients that are enrolled in the Company's clinical trials that will ultimately be treated with the Company's Hemopurifier; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit:

https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

Wednesday, December 11, 2024

Biopharma Stock Alert - Poseida Therapeutics, Inc. (Nasdaq: PSTX) Gains on Big Pharma Acquisition News

Biopharma Stock Alert - Poseida Therapeutics, Inc. (Nasdaq: PSTX) Gains on Big Pharma Acquisition News: Biopharma Stock Alert - Poseida Therapeutics, Inc. (Nasdaq: PSTX) Gains on Big Pharma Acquisition News

Biopharma Stock Candel Therapeutics, Inc. (Nasdaq: CADL) Sees Big Gains on News of Phase 3 Prostate Cancer Trial

Biopharma Stock Candel Therapeutics, Inc. (Nasdaq: CADL) Sees Big Gains on News of Phase 3 Prostate Cancer Trial: Biopharma Stock Candel Therapeutics, Inc. (Nasdaq: CADL) Sees Big Gains on News of Phase 3 Prostate Cancer Trial

Friday, December 6, 2024

November Wrap-up; New Stocks to Watch in Biotech, Mining and Tech; (Nasdaq: $CERO) (CSE: $HEAL.CN) (Nasdaq: $GELS) (CSE: $DMC.CN) (CSE: $MERC.CN) (CSE: $ARMY.CN) (NASDAQ: $ARBE) (NYSE: $GNS)

November Wrap-up; New Stocks to Watch in Biotech, Mining and Tech; (Nasdaq: $CERO) (CSE: $HEAL.CN) (Nasdaq: $GELS) (CSE: $DMC.CN) (CSE: $MERC.CN) (CSE: $ARMY.CN) (NASDAQ: $ARBE) (NYSE: $GNS)

December 6, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the biotech, mining and tech sectors.

The newest biotech companies are involved in cancer treatment, neuroinflammatory disorders and nutrient and drug delivery, respectively.

The latest mining companies are all CSE (Canadian Stock Exchange) listed.

The newest tech companies are involved in safety for autonomous vehicles and AI.

New stocks added today: CERo Therapeutics Holdings, Inc. (Nasdaq: CERO), Restart Life Sciences Corp. (CSE:HEAL), Gelteq Limited (Nasdaq:GELS), Dunbar Metals Corp. (CSE: DMC), Mercado Minerals Ltd. (CSE:MERC), Armory Mining Corp. (CSE: ARMY), Arbe Robotics Ltd. (NASDAQ:ARBE), Genius Group (NYSE: GNS).

Read this in full at https://www.investorideas.com/news/2024/main/12061Stocks.asp

New Stocks Added to the Tech Directories:

Arbe Robotics Ltd. (NASDAQ:ARBE) a global leader in Perception Radar solutions, is spearheading a radar revolution, enabling safe driver-assist systems today while paving the way to full autonomous-driving. Arbe's radar technology is 100 times more detailed than any other radar on the market and is a critical sensor for L2+ and higher autonomy. The company is empowering automakers, Tier 1 suppliers, autonomous ground vehicles, commercial and industrial vehicles, and a wide array of safety applications with advanced sensing and paradigm changing perception. Arbe is based in Tel Aviv, Israel, and has offices in China, Germany, and the United States.

Genius Group (NYSE: GNS) is a leading provider of AI powered, digital-first education and acceleration solutions for the future of work. Genius Group serves 5.4 million users in over 100 countries through its Genius City model and online digital marketplace of AI training, AI tools and AI talent. It provides personalized, entrepreneurial AI pathways combining human talent with AI skills and AI solutions at the individual, enterprise and government level.

New Stocks Added to the Mining Directories:

Dunbar Metals Corp. (CSE: DMC) is engaged in the business of the acquisition and exploration of mineral properties in Canada. The Company holds a 100% interest in and to mineral claims totaling 6,949.80 hectares comprising the Gorilla Lake Property, located in North Saskatchewan, Canada, subject to a royalty obligation. The Company’s secondary objective is to locate and develop economic precious and base metals properties of merit.

Mercado Minerals Ltd. (CSE:MERC) Formerly Heartfield Mining Corp. –is a company involved in the business of acquiring and exploring mineral properties in Canada and the United States. Mercado has been primarily involved in the exploration and evaluation of the Porter Property, located within Alberni Mining Divisions of British Columbia.

Armory Mining Corp. (CSE: ARMY)- formerly Spey Resources Corp - is a junior mineral exploration company. Spey is engaged in the business of acquiring, exploring and evaluating natural resource properties. Spey has an option to acquire a 100% undivided interest in the Silver Basin Property (the “Property”) located in the Revelstoke Mining Division, of southern British Columbia.

New Stocks Added to the Biotech Directories:

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in early 2025 for AML.

Restart Life Sciences Corp. (CSE:HEAL) Formerly Nova Mentis Life Science Corp - is a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Their mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

Gelteq Limited (Nasdaq:GELS) Headquartered in Melbourne, Australia, Gelteq is a global biotechnology company that specializes in the formulation, development, and manufacturing of an innovative ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control.

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

800 665 0411

Disclaimer

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investorideas.com newswire, breaking biotechnology and pharma news

Friday, December 20, 2024

Wednesday, December 11, 2024

Friday, December 6, 2024